Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel Free SCPS Stock Alerts

Scopus BioPharma (SCPS) Competitors

Scopus BioPharma logo
$0.0004 0.00 (0.00%)
As of 10/13/2026 01:56 PM Eastern
Compare

SCPS vs. CARM, TRVN, BPTH, NAVB, and PXMD

Should you buy Scopus BioPharma stock or one of its competitors? Scopus BioPharma's main competitors and comparable companies include Carisma Therapeutics (CARM), Trevena (TRVN), Bio-Path (BPTH), Navidea Biopharmaceuticals (NAVB), and PaxMedica (PXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scopus BioPharma compare to Carisma Therapeutics?

Scopus BioPharma (NASDAQ:SCPS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Scopus BioPharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Carisma Therapeutics -254.28%N/A -192.17%

Scopus BioPharma has a beta of -0.32, indicating that its stock price is 132% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.6, indicating that its stock price is 1,060% less volatile than the broader market.

Scopus BioPharma has higher earnings, but lower revenue than Carisma Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Carisma Therapeutics Neutral

44.3% of Carisma Therapeutics shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Scopus BioPharma beats Carisma Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Scopus BioPharma compare to Trevena?

Trevena (NASDAQ:TRVN) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Scopus BioPharma Neutral

Trevena has a beta of -1.99, suggesting that its share price is 299% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.32, suggesting that its share price is 132% less volatile than the broader market.

Scopus BioPharma has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.14-$40.29M-$47.04N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Scopus BioPharma N/A N/A N/A

13.6% of Trevena shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Scopus BioPharma beats Trevena on 4 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Bio-Path has a beta of -0.44, meaning that its stock price is 144% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market.

5.7% of Bio-Path shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Scopus BioPharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Scopus BioPharma's return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Scopus BioPharma N/A N/A N/A

Summary

Scopus BioPharma beats Bio-Path on 5 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Navidea Biopharmaceuticals?

Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Scopus BioPharma has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Navidea Biopharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Scopus BioPharma's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Scopus BioPharma N/A N/A N/A

PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.32, suggesting that its stock price is 132% less volatile than the broader market.

4.9% of PaxMedica shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Scopus BioPharma Neutral

Summary

Scopus BioPharma beats PaxMedica on 5 of the 6 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCPS vs. The Competition

Export
MetricScopus BioPharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7K$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E RatioN/A626.67195.9718.94
Price / SalesN/A746.64564.5078.56
Price / CashN/A84.0876.6852.75
Price / BookN/A9.1510.515.92
Net Income-$11.61M$2.82B$3.50B$380.90M
7 Day PerformanceN/A-4.55%-4.32%-4.38%
1 Month PerformanceN/A-8.50%-8.64%-7.25%
1 Year PerformanceN/A-6.15%2.05%-4.95%

Scopus BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$7KN/AN/A9
CARM
Carisma Therapeutics
N/A$0.00
flat		N/A-98.9%$21K$10.77M0.0020
TRVN
Trevena
N/A$0.01
flat		N/A+450.0%$12K$443KN/A23
BPTH
Bio-Path
N/A$0.00
-60.0%		N/A-99.6%$11KN/AN/A10
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...
Weiss Ratings | Sponsoredtc pixel
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...
Behind the Markets | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel